About Vetiqure

Our Company

Vetiqure – innovator in gentle cancer treatment

Vetiqure AB is a wholly owned subsidiary of Scandinavian ChemoTech AB, a dynamic Life Science company that focus on developing technologies and therapies for various cancer tumours and advanced pain control for cancer. The Company has extensive experience in Tumour Specifik Electroporation™ (TSE), which forms the basis of the Company’s therapeutic areas. Currently, the Company is offering treatments for a various forms of cancer tumours. The Company is based at Medicon Village in Lund, Sweden.

Launching the vetIQure™

Following extensive research and development, Vetiqure AB launched the vetIQure™ device. With its new patented technology, TSE (Tumour Specific Electroporation™), it offers safe yet effective and flexible treatment capabilities. vetIQure™ has been designed to achieve positive clinical outcomes on a level previously not possible. vetIQure™, is designed for animals based on a technology developed to treat humans. Its technnology TSE makes it possible to treat non-responsive tumours and tumours in sensitive locations.

vetIQure™ is continuously being introduced to the veterinarian market and we are looking forward to close collaborations with both customers and distributors in Europe and the rest of the world.

Vetiqure values and strategy

Our values

Our heart and soul

By being devoted to clinical development and scientific excellence, Vetiqure AB aspires to be a force for better cancer care for our pets. Our aim is to always deliver cost- and treatment efficient technologies that improve the quality of life of those suffering from cancer, and their owners.

What we believe

Many medical technical companies focus on science and clinical outcomes, but put less emphasis on the cost for the patients. At Vetiqure, we want to address these issues. We believe that it is possible to provide cancer treatment with a solid scientific base and excellent clinical outcomes that are cost-efficient enough to be made available to everyone who needs it.

Strategic development

By using the global cancer epidemic as a strategic point of departure when developing our products, we want to develop safe treatment methods for indications where existing therapies often fail or are associated with great suffering or severe side effects.

Our Products

News & Press releses

Get in touch

Are you interested to know more?

Our team is here to help with any questions regarding our products, patents, or anything else you want to know.

About

Publications

General